A Response to: Letter to the Editor Regarding "Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants".

Johnna Perdrizet Emily K Horn Winniefer Nua Judith Perez-Peralta Jennifer Nailes Jaime Santos Anna Ong-Lim

Infect Dis Ther

Infectious and Tropical Disease, Department of Pediatrics, College of Medicine-Philippine General Hospital, University of the Philippines, Manila, Philippines.

Published: June 2022

This communication seeks to address the questions of Dhere and colleagues in their letter on our study "Cost-effectiveness of the 13-valent pneumococcal conjugate vaccine (PCV13) versus lower-valent alternatives in Filipino infants." We hope to provide clarity on each of the three potential misunderstandings of our cost-effectiveness analysis that were raised by Dhere and colleagues.

Download full-text PDF	Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9124259	PMC
http://dx.doi.org/10.1007/s40121-022-00639-3	DOI Listing

Publication Analysis

Top Keywords

"cost-effectiveness 13-valent

13-valent pneumococcal

pneumococcal conjugate

conjugate vaccine

vaccine pcv13

pcv13 versus

versus lower-valent

lower-valent alternatives

alternatives filipino

filipino infants"

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!